SEO Title (60–75 characters)
VERQUVO-5MG-14 TABLET (Vericiguat 5 mg) Heart Failure Tablets
SEO Description (175–200 characters)
VERQUVO-5MG-14 TABLET contains Vericiguat 5 mg, a prescription soluble guanylate cyclase stimulator used to reduce the risk of cardiovascular death and heart failure hospitalization in eligible adults.
H1 (20–50 characters)
VERQUVO-5MG-14 TABLET
VERQUVO-5MG-14 TABLET (Vericiguat 5 mg): Comprehensive Guide and Benefits
Introduction to VERQUVO-5MG-14 TABLET (Vericiguat 5 mg)
VERQUVO-5MG-14 TABLET (Vericiguat 5 mg): A Soluble Guanylate Cyclase (sGC) Stimulator
VERQUVO-5MG-14 TABLET is a prescription-only cardiovascular medicine containing Vericiguat 5 mg. It belongs to the soluble guanylate cyclase (sGC) stimulator class and is used in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) who have recently experienced worsening heart failure requiring hospitalization or intravenous diuretic therapy. It is used together with standard heart failure treatments.
Vericiguat enhances the nitric oxide–sGC–cGMP signaling pathway, helping improve blood vessel relaxation and cardiac function. It has been shown to reduce the risk of cardiovascular death and heart failure hospitalization in appropriately selected patients. Treatment should only be started and monitored by a qualified healthcare professional because blood pressure, kidney function, and overall clinical status require ongoing assessment.
Key Benefits of VERQUVO-5MG-14 TABLET (Vericiguat 5 mg)
Helps reduce the risk of cardiovascular death in eligible heart failure patients.
Lowers the likelihood of hospitalization due to worsening heart failure.
Complements guideline-directed heart failure therapy.
Improves nitric oxide signaling involved in cardiovascular function.
Provides once-daily oral dosing for convenient administration.
How VERQUVO-5MG-14 TABLET (Vericiguat 5 mg) Works
Vericiguat directly stimulates soluble guanylate cyclase (sGC) while also increasing the enzyme's sensitivity to endogenous nitric oxide. This enhances intracellular cyclic guanosine monophosphate (cGMP) production, promoting relaxation of vascular smooth muscle, improving endothelial function, and supporting cardiovascular performance. By restoring impaired nitric oxide signaling commonly seen in chronic heart failure, vericiguat helps reduce adverse cardiovascular outcomes when used alongside standard heart failure therapy.
Usage Instructions for VERQUVO-5MG-14 TABLET
Take exactly as prescribed by your healthcare provider.
Swallow the tablet once daily with food.
Take the medicine at approximately the same time each day.
Attend regular follow-up visits to monitor blood pressure, kidney function, and heart failure status.
Do not discontinue or adjust the dose without consulting your healthcare provider.
Medicinal Advantages of VERQUVO-5MG-14 TABLET
Clinically proven to reduce heart failure hospitalization risk.
Helps decrease cardiovascular mortality in eligible patients.
Novel mechanism targeting impaired nitric oxide signaling.
Convenient once-daily oral therapy.
Can be combined with standard evidence-based heart failure medications.
NOTE: VERQUVO-5MG-14 TABLET is a prescription-only medicine. It should be used only under specialist supervision. It is contraindicated during pregnancy because of the risk of fetal harm, and women of reproductive potential should use effective contraception during treatment.
Off-Label Uses of VERQUVO-5MG-14 TABLET
Vericiguat is primarily approved for selected adults with symptomatic chronic heart failure. Off-label use should only be considered by experienced healthcare professionals based on individual clinical circumstances.
Individualized management of selected heart failure patients.
Specialist-directed cardiovascular treatment strategies.
Research-based use in carefully selected patients where clinically appropriate.
Disclaimer: Off-label uses should only occur under physician supervision and may not be approved in all countries.
Expert Advice for Optimal Use
Take the medicine with food every day.
Continue all prescribed heart failure medications unless instructed otherwise.
Monitor your blood pressure regularly.
Report dizziness, fainting, or worsening heart failure symptoms promptly.
Follow recommended dietary and lifestyle advice for heart failure.
Keep all scheduled cardiology appointments.
Precautions
Cardiovascular Health
Use only under the supervision of a cardiologist or qualified healthcare provider. Blood pressure should be monitored because symptomatic hypotension may occur.
Liver & Kidney Function
Patients with impaired kidney or liver function should be evaluated before and during treatment. Your healthcare provider may recommend periodic laboratory monitoring.
Pregnancy & Breastfeeding
Do not use during pregnancy, as vericiguat may cause fetal harm. Women of reproductive potential should have pregnancy testing before treatment and use effective contraception during therapy and for one month after stopping treatment. Consult your healthcare provider regarding breastfeeding.
Drug Interactions
Do not use vericiguat together with other soluble guanylate cyclase stimulators such as riociguat. Inform your healthcare provider about all prescription medicines, over-the-counter drugs, vitamins, and herbal supplements before starting treatment.
Existing Medical Conditions
Inform your healthcare provider if you have severe hypotension, significant kidney disease, liver disease, anemia, or any other chronic cardiovascular condition before beginning therapy.
Storage Instructions
Store below 30°C or according to the package label.
Keep tablets in the original blister pack.
Protect from excessive heat, moisture, and direct sunlight.
Keep out of the reach of children and pets.
Do not use after the expiry date.
Frequently Asked Questions (FAQs)
Q: What is VERQUVO-5MG-14 TABLET used for?
A: It is used to reduce the risk of cardiovascular death and hospitalization in eligible adults with symptomatic chronic heart failure with reduced ejection fraction.
Q: What is the active ingredient in VERQUVO-5MG-14 TABLET?
A: Each tablet contains Vericiguat 5 mg, a soluble guanylate cyclase stimulator.
Q: Should VERQUVO-5MG-14 TABLET be taken with food?
A: Yes. It should be taken once daily with food to help ensure appropriate absorption.
Q: Can I stop taking VERQUVO-5MG-14 TABLET if I feel better?
A: No. Continue taking the medicine unless your healthcare provider advises you to stop.
Q: Is VERQUVO-5MG-14 TABLET safe during pregnancy?
A: No. It is contraindicated during pregnancy because it may cause fetal harm.
Q: What are the common side effects?
A: Commonly reported side effects include low blood pressure (hypotension), dizziness, and anemia. Contact your healthcare provider if symptoms are severe or persistent.
Q: Is VERQUVO-5MG-14 TABLET available without a prescription?
A: No. It is a prescription-only medicine that should be used under the supervision of a qualified healthcare professional.
Product Tags
VERQUVO-5MG-14 TABLET, Vericiguat 5 mg, Vericiguat Tablet, Soluble Guanylate Cyclase Stimulator, sGC Stimulator, Heart Failure Medicine, Chronic Heart Failure Treatment, HFrEF Therapy, Cardiovascular Medicine, Prescription Heart Failure Drug, Verquvo 5 mg, Heart Failure Hospitalization Prevention, Cardiovascular Death Risk Reduction, Once Daily Heart Failure Tablet, Cardiology Medication, Nitric Oxide Pathway, Guideline-Directed Heart Failure Therapy, Vericiguat Prescription, Oral Heart Failure Treatment, Heart Failure Tablets
